Guido Ferrari

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
    Jeffrey R Currier
    The US Military HIV Research Program, Suite 200, 13 Taft Court, Rockville, MD 20851, USA
    J Immunol Methods 260:157-72. 2002
  2. pmc Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Pathog 7:e1001273. 2011
  3. pmc High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cytometry A 79:603-12. 2011
  4. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013
  5. pmc An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
    Guido Ferrari
    Duke University Medical Center, Department of Surgery, P O Box 2926, Durham, NC 27710, USA
    J Virol 85:7029-36. 2011
  6. ncbi request reprint Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 173:2126-33. 2004
  7. ncbi request reprint HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians
    Guido Ferrari
    Duke University, Durham, NC, USA
    Hum Immunol 65:648-59. 2004
  8. ncbi request reprint Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance
    Susan S Kaplan
    Department of Medicine, Duke University Medical Center, Durham, NC 22710, USA
    AIDS Res Hum Retroviruses 21:13-6. 2005
  9. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
  10. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013

Detail Information

Publications39

  1. ncbi request reprint A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
    Jeffrey R Currier
    The US Military HIV Research Program, Suite 200, 13 Taft Court, Rockville, MD 20851, USA
    J Immunol Methods 260:157-72. 2002
    ..The size, shape and appearance of the spots produced using this peptide panel provided a standard for the establishment of acceptance criteria of spots for the evaluation of ELISPOT plates using an automated reader system...
  2. pmc Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Pathog 7:e1001273. 2011
    ....
  3. pmc High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cytometry A 79:603-12. 2011
    ....
  4. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013
    ..Here we discuss the HIV-1 envelope epitopes targeted by ADCC antibodies in the context of the potential protective capacities of ADCC. ..
  5. pmc An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
    Guido Ferrari
    Duke University Medical Center, Department of Surgery, P O Box 2926, Durham, NC 27710, USA
    J Virol 85:7029-36. 2011
    ..These data demonstrate that the epitope defined by MAb A32 is a major target on gp120 for plasma ADCC activity...
  6. ncbi request reprint Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 173:2126-33. 2004
    ....
  7. ncbi request reprint HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians
    Guido Ferrari
    Duke University, Durham, NC, USA
    Hum Immunol 65:648-59. 2004
    ..These data represent the first report of correlating HLA phenotype and HIV-specific cell-mediated immune responses among infected Ethiopians and may be useful in designing cytotoxic T lymphocyte-inducing vaccines for this part of Africa...
  8. ncbi request reprint Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance
    Susan S Kaplan
    Department of Medicine, Duke University Medical Center, Durham, NC 22710, USA
    AIDS Res Hum Retroviruses 21:13-6. 2005
    ..Thus, CD4(+)/VL discordance can be maintained for periods exceeding 5 years in some patients receiving PI-based HAART without significant evolution of HIV resistance...
  9. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
    ..We show that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modulate vaccine-induced immunity by diminishing ADCC effector function...
  10. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
    ..Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space. ..
  11. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  12. pmc Acute HIV-1 infection in the Southeastern United States: a cohort study
    Mehri S McKellar
    Duke University, Durham, NC 27710, USA
    AIDS Res Hum Retroviruses 29:121-8. 2013
    ..Highlighting the challenges of diagnosing AHI, less than half of the patients were diagnosed at the first healthcare visit. Women made up a small proportion despite increasing numbers in our clinics...
  13. pmc Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication
    Stephanie A Freel
    Department of Surgery, Duke University Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:6835-46. 2012
    ....
  14. pmc Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination
    Stephanie A Freel
    Duke University Human Vaccine Institute, Departments of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 84:4998-5006. 2010
    ..Our data define attributes of an antiviral CD8(+) T-cell response that may be optimized in the search for an efficacious HIV-1 vaccine...
  15. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  16. ncbi request reprint Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function
    Gregory D Sempowski
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Immunol 25:462-72. 2005
    ....
  17. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  18. pmc Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk
    Genevieve G A Fouda
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 87:6986-99. 2013
    ..This study shows that systemic MVA prime followed by either intranasal or systemic protein boosts can elicit strong humoral responses in breast milk and may be a useful strategy to interrupt postnatal HIV-1 transmission...
  19. pmc HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
    J Virol 86:7496-507. 2012
    ..Improved vaccination strategies will be needed to drive persistent stimulation of antibody clonal lineages to induce affinity maturation that results in highly mutated HIV-1 Env-reactive antibodies...
  20. pmc Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum
    James Friedman
    Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States
    PLoS ONE 7:e37648. 2012
    ..Therefore, characterization of HIV-specific antibodies produced by B cells in milk could guide the development of vaccines that elicit protective mucosal antibody responses...
  21. pmc CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection
    Marc A Frahm
    Center for AIDS Research, Duke University Medical Center, Durham, NC 22710, USA
    J Immunol 188:4289-96. 2012
    ..Therefore, DP T cells represent a highly reactive cell population during acute HIV infection, which responds independently from the traditional T cell compartments...
  22. doi request reprint Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
    Nicole L Yates
    Duke Human Vaccine Institute, Durham, NC 27710, USA
    Sci Transl Med 6:228ra39. 2014
    ..These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials. ..
  23. pmc Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design
    Nancy Gasper-Smith
    Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 82:7700-10. 2008
    ....
  24. doi request reprint Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 88:3329-39. 2014
    ....
  25. pmc Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome
    Hongshuo Song
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Retrovirology 9:89. 2012
    ....
  26. pmc HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies
    Genevieve G Fouda
    Duke Human Vaccine Institute, Duke University Medical Center, Box 103020, Durham, NC 27710, USA
    J Virol 85:9555-67. 2011
    ..These results suggest that plasma-derived IgG antibodies mediate the majority of the low-level HIV neutralization and ADCC activity in breast milk...
  27. pmc Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy
    Cynthia Gay
    Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
    PLoS ONE 6:e19617. 2011
    ..We studied subjects with AHI prospectively to develop better treatment and public health interventions...
  28. ncbi request reprint Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control
    Susan A Sufka
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Infect Dis 187:1027-37. 2003
    ..These findings suggest that discordant responses may be related to enhanced HIV-directed immune responses, diminished cellular activation, decreased viral replication capacity, and preservation of non-syncytium-inducing virus strains...
  29. ncbi request reprint A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions
    Matthew E Harris
    Walter Reed Army Institute of Research, Washington, D C, USA
    AIDS Res Hum Retroviruses 19:1125-33. 2003
    ..Although immunological responses must be considered, from a phylogenetic perspective, there is no compelling support for use of Ethiopian subtype C sequences, compared to other subtype C, as vaccine prototype strains...
  30. ncbi request reprint Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials
    Josephine H Cox
    U S Military HIV Research Program, Rockville, MD 20850, USA
    AIDS Res Hum Retroviruses 21:68-81. 2005
    ..This study highlights the need for better standardization of protocols and reagents to obtain reliable and reproducible data that may support immunogenicity studies, vaccine regulatory submissions, and licensure...
  31. pmc Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection
    Michael R Betts
    Laboratory of Immunology, Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:4512-7. 2005
    ..These data suggest that control of HIV by vaccine-elicited HIV-specific T cell responses may be difficult, even when the T cell response has those characteristics predicted to provide optimal protection...
  32. ncbi request reprint Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians
    Jeffrey R Currier
    The U S Military HIV Research Program, Rockville, Maryland 20850, USA
    AIDS Res Hum Retroviruses 21:239-45. 2005
    ..Efforts to optimize the cross-reactivity of vaccine-induced CD8 T cells may need to focus on the relative immunogenicity of minor sequence variation...
  33. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
    ..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...
  34. ncbi request reprint Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development
    Michael R Betts
    University of Pennsylvania, Department of Microbiology, 522E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    Expert Rev Vaccines 5:505-16. 2006
    ..Furthermore, potential protective characteristics will be proposed that may ultimately be required for an effective vaccine designed to stimulate cellular immunity against HIV-1...
  35. ncbi request reprint Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
    Paul A Goepfert
    University of Alabama at Birmingham, 908 20th Street South, CCB 328, Birmingham, AL 35294, USA
    Vaccine 25:510-8. 2007
    ..Use of the recombinant proteins NefTat and gp120(W61D) formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system...
  36. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  37. ncbi request reprint Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
    Vaccine 26:215-23. 2008
    ..Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic...
  38. ncbi request reprint Standardization and validation issues of the ELISPOT assay
    Sylvia Janetzki
    ZellNet Consulting Inc, Fort Lee, NJ, USA
    Methods Mol Biol 302:51-86. 2005
    ..This chapter will give the experienced scientists as well as newcomers to the field an overview over the major standardization issues for each step of the protocol. Guidelines are given on how to validate the ELISPOT performance...
  39. ncbi request reprint Measurement of cytokine release at the single cell level using the ELISPOT assay
    Josephine H Cox
    U S Military HIV Research Program, Henry M Jackson Foundation for the Advancement of Military Medicine, 13 Taft Court, Rockville, MD 20850, USA
    Methods 38:274-82. 2006
    ..The history, applications, validation process, and future challenges of the ELISPOT assay are discussed in this chapter...

Research Grants9

  1. Poly-functional analyses of vaccine-induced T cell responses
    Guido Ferrari; Fiscal Year: 2010
    ..Overall, these findings will shed new insights on the importance and fate of vaccine-induced T cell responses in controlling HIV-infection. ..
  2. HIV Vaccine Induced CTL: Qualitative/Functional Analyses
    Guido Ferrari; Fiscal Year: 2004
    ..By yielding new insights into the quality of vaccine-induced CTL, these studies could greatly impact the further development of vector-based vaccines. ..
  3. Poly-functional analyses of vaccine-induced T cell responses
    Guido Ferrari; Fiscal Year: 2007
    ..Overall, these findings will shed new insights on the importance and fate of vaccine-induced T cell responses in controlling HIV-infection. ..